The Food and Drug Administration (FDA) has approved a treatment for the prevention of RSV among infants and toddlers, making it the first preventive for the common virus that surged last winter among small children.
The FDA approved nirsevimab-alip, or Beyfortus, for the prevention of RSV among newborns and infants born during or entering into their first RSV season, which typically starts in the fall, peaks in the winter and ends in the spring.
Beyfortus is a monoclonal antibody administered in one dose. The safety of efficacy of the medicine is supported by three clinical trials, according to the FDA’s release on Monday.
